GSK656和阿米卡星对脓肿分枝杆菌的体外联合药物敏感性研究

doi:10.19982/j.issn.1000-6621.20210465

摘要/Abstract

摘要：

目的: 评价3-氨甲基-4-卤代苯并噁唑类化合物GSK656与阿米卡星联合用药对脓肿分枝杆菌分离株的体外抑菌作用。 方法: 收集首都医科大学附属北京胸科医院菌株库保存的30株脓肿分枝杆菌,采用微孔阿尔玛蓝检测法(MABA法)测定GSK656和阿米卡星对脓肿分枝杆菌的体外最低抑菌浓度(MIC)。采用棋盘稀释法进行联合药物敏感性试验,通过分级抑菌浓度指数判断联合抑菌的效果。 结果: GSK656对脓肿分枝杆菌的MIC为0.063~4.000mg/L;阿米卡星对脓肿分枝杆菌的MIC为4.000~16.000mg/L。GSK656对脓肿分枝杆菌分离株的MIC₅₀和MIC₉₀分别为0.250mg/L和2.000mg/L,阿米卡星对脓肿分枝杆菌分离株的MIC₅₀和MIC₉₀分别为8.000mg/L和16.000mg/L。GSK656与阿米卡星联合使用时,5株(16.7%)脓肿分枝杆菌分离株表现为协同作用,1株(3.3%)分离株表现为拮抗作用,其他分离株(80.0%,24/30)表现为无关作用。 结论: GSK656与阿米卡星的体外联合用药对脓肿分枝杆菌表现出良好的抑菌效果,可为临床用药提供一定参考价值。

关键词: GSK656, 抗菌药, 分枝杆菌,非典型性, 药物评价

Abstract:

Objective: To investigate the in vitro synergistic effect of GSK656, a novel member of 3-aminomethyl 4-halogen benzoxaboroles, with aminoglycoside-amikacin against Mycobacterium abscessus. Methods: Thirty clinical M.abscessus isolates were collected from the Biobank of Beijing Chest Hospital affiliated to Capital Medical University. Minimum inhibitory concentration (MIC) were determined using microdilution MABA assay. The checkerboard titration method was used to explore the in vitro synergistic effect between GSK656 and amikacin against M.abscessus isolates. Fractional inhibitory concentration index was calculated to determine the combined effects of these two compounds. Results: GSK656 and amikacin showed potent antibacterial activities against M.abscessus. The MIC of M.abscessus ranged from 0.063 to 4.000 mg/L for GSK656, the MIC₅₀ and MIC₉₀ of which were 0.250 and 2.000 mg/L, respectively. The MIC ranged from 4.000 to 16.000 mg/L for amikacin, the MIC₅₀ and MIC₉₀ of which were 8.000 and 16.000 mg/L, respectively. For GSK656-amikacin combination, only 1 strain (3.3%) had antagonistic effect. Synergy for GSK656-amikacin combination was observed in 5 isolates (16.7%); antagonism was observed in one isolate (3.3%); while the remaining isolates (80.0%) showed indifference. Conclusion: GSK656 and amikacin holds potent antibacterial activity against M.abscessus, which provids important clinical benefit for treatment of. M.abscessus infections.

Key words: GSK656, Antimicrobial agent, Mycobacteria,atypical, Drug evaluation

中图分类号:

陈磊, 郭海萍, 逄宇, 刘光福, 潘兆宝, 韩守华, 程娟, 李姗姗. GSK656和阿米卡星对脓肿分枝杆菌的体外联合药物敏感性研究[J]. 中国防痨杂志, 2022, 44(3): 234-238. doi: 10.19982/j.issn.1000-6621.20210465

CHEN Lei, GUO Hai-ping, PANG Yu, LIU Guang-fu, PAN Zhao-bao, HAN Shou-hua, CHENG Juan, LI Shan-shan. In vitro synergistic activities of GSK656 with amikacin against Mycobacterium abscessus[J]. Chinese Journal of Antituberculosis, 2022, 44(3): 234-238. doi: 10.19982/j.issn.1000-6621.20210465

图/表 4

表1

表2

表3

表4

参考文献 17

[1]	Chen CY, Chen HY, Chou CH, et al. Pulmonary infection caused by nontuberculous mycobacteria in a medical center in Taiwan, 2005—2008. Diagn Microbiol Infect Dis, 2012, 72(1):47-51. doi: 10.1016/j.diagmicrobio.2011.09.009. doi: 10.1016/j.diagmicrobio.2011.09.009 URL
[2]	Lee MR, Sheng WH, Hung CC, et al. Mycobacterium abscessus Complex Infections in Humans. Emerg Infect Dis, 2015, 21(9):1638-1646. doi: 10.3201/2109.141634. doi: 10.3201/2109.141634
[3]	Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet, 2013, 381(9877):1551-1560. doi: 10.1016/S0140-6736(13)60632-7. doi: 10.1016/S0140-6736(13)60632-7 URL
[4]	Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354(6313):751-757. doi: 10.1126/science.aaf8156. doi: 10.1126/science.aaf8156 URL
[5]	Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med, 2009, 180(9):896-902. doi: 10.1164/rccm.200905-0704OC. doi: 10.1164/rccm.200905-0704OC URL
[6]	Li X, Hernandez V, Rock FL, et al. Discovery of a Potent and Specific M.tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem, 2017, 60(19):8011-8026. doi: 10.1021/acs.jmedchem.7b00631. doi: 10.1021/acs.jmedchem.7b00631 URL
[7]	Dong W, Li S, Wen S, et al. In Vitro Susceptibility Testing of GSK656 against Mycobacterium Species. Antimicrob Agents Chemother, 2020, 64(2):e01577-19. doi: 10.1128/AAC.01577-19. doi: 10.1128/AAC.01577-19
[8]	Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J, 2013, 42(6):1604-1613. doi: 10.1183/09031936.00149212. doi: 10.1183/09031936.00149212 pmid: 23598956
[9]	Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute, 2011.
[10]	Zhang Z, Lu J, Liu M, et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. Int J Antimicrob Agents, 2017, 49(3):383-386. doi: 10.1016/j.ijantimicag.2016.12.003. doi: 10.1016/j.ijantimicag.2016.12.003 URL
[11]	Pang Y, Tan Y, Chen J, et al. Diversity of nontuberculous mycobacteria in eastern and southern China: a cross-sectional study. Eur Respir J, 2017, 49(3):1601429. doi: 10.1183/13993003.01429-2016. doi: 10.1183/13993003.01429-2016 URL
[12]	Piersimoni C, Scarparo C. Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis, 2008, 8(5):323-334. doi: 10.1016/S1473-3099(08)70100-2. doi: 10.1016/S1473-3099(08)70100-2 pmid: 18471777
[13]	张智健. 脓肿分枝杆菌复合群的药物敏感性分析及其对克拉霉素的耐药机制研究. 北京: 中国人民解放军总医院, 2015.
[14]	Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother, 2012, 67(4):810-818. doi: 10.1093/jac/dkr578. doi: 10.1093/jac/dkr578 URL
[15]	Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4):367-416. doi: 10.1164/rccm.200604-571ST. doi: 10.1164/rccm.200604-571ST URL
[16]	Prammananan T, Sander P, Brown BA, et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis, 1998, 177(6):1573-1581. doi: 10.1086/515328. doi: 10.1086/515328 pmid: 9607835
[17]	Philley JV, Wallace RJ Jr, Benwill JL, et al. Preliminary Results of Bedaquiline as Salvage Therapy for Patients with Nontuberculous Mycobacterial Lung Disease. Chest, 2015, 148(2):499-506. doi: 10.1378/chest.14-2764. doi: S0012-3692(15)50346-2 pmid: 25675393

关系	菌株数	MIC范围(mg/L)				FICI范围
关系	菌株数	GSK656(单药)	阿米卡星(单药)	GSK656(联合)	阿米卡星(联合)	FICI范围
协同	5	0.250~2.000	4.000~16.000	0.063~0.500	1.000~4.000	0.250~0.500
无关	24	0.063~4.000	4.000~16.000	0.063~2.000	2.000~16.000	0.625~2.000
拮抗	1	0.250	16.000	0.125	32.000	2.500